Drug intelligence / Profile preview

fluoxetine

Development stage
Approved
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Oral
01

Overview

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant used to treat major depressive disorder, obsessive-compulsive disorder (OCD), bulimia nervosa, panic disorder, and premenstrual dysphoric disorder (PMDD). It is also approved for use in children and adolescents for depression and has been used off-label for other conditions such as anxiety disorders and premature ejaculation. Fluoxetine works by inhibiting the reuptake of serotonin in the brain, thereby increasing its availability to help regulate mood. Developed by Eli Lilly and Company in 1972 and first approved in 1987/1986, it was one of the first SSRIs introduced to clinical practice. Fluoxetine is available as a generic medication worldwide. It may be combined with olanzapine under the brand name Symbyax for treatment-resistant depression or bipolar I depressive episodes.

Brand names
ProzacSarafemRapifluxSelfemraProzac WeeklySymbyax
Other names
Fluoxetine HydrochloridePLIVA 648PLIVA648PLIVA-648
02

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on fluoxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluoxetine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call